Drug and Alcohol Dependence
Volume 107, Issue 2 , Pages 188-195 , 1 March 2010

A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers

  • Andrea H. Weinberger

      Affiliations

    • Program for Research in Smokers with Mental Illness (PRISM), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • Substance Abuse Center (SAC), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • Corresponding Author InformationCorresponding author at: Department of Psychiatry, Yale University School of Medicine, 34 Park Street, SAC, Room S-211, New Haven, CT 06519, USA. Tel.: +1 203 974 7598; fax: +1 203 974 7366.
    • ,
  • Erin L. Reutenauer

      Affiliations

    • Program for Research in Smokers with Mental Illness (PRISM), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • Substance Abuse Center (SAC), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • ,
  • Peter I. Jatlow

      Affiliations

    • Departments of Laboratory Medicine and Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • ,
  • Stephanie S. O’Malley

      Affiliations

    • Substance Abuse Center (SAC), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • ,
  • Marc N. Potenza

      Affiliations

    • Substance Abuse Center (SAC), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • Child Study Center, Yale University School of Medicine, New Haven, CT 06519, USA
    • ,
  • Tony P. George

      Affiliations

    • Program for Research in Smokers with Mental Illness (PRISM), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • Substance Abuse Center (SAC), Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
    • Division of Addiction Psychiatry, Department of Psychiatry, University of Toronto and Schizophrenia Program, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, M5T 1R8 Canada

Received 31 July 2009 ,Revised 16 October 2009 ,Accepted 19 October 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ The Clinicaltrials.gov Registration No. for this trial, “Usefulness of Selegiline as an Aid to Quit Smoking,” is NCT00129311.

PII: S0376-8716(09)00399-8

doi: 10.1016/j.drugalcdep.2009.10.009

Drug and Alcohol Dependence
Volume 107, Issue 2 , Pages 188-195 , 1 March 2010

Article Tools

* Image Usage & Resolution